D amphetamine sulfate amph

High molecular weight (HMV) poly (I:C) was purchased from InvivoGen. Poly (I:C) was dissolved in endotoxin-free saline solution, (4.0 mg/kg) and injected in the lateral vein of the tail of F0 pregnant dams. To assess the efficacy of poly (I:C) injection, all pregnant rats were weighed for the first 3 days after the administration of either poly (I:C) or endotoxin-free saline to evaluate potential weight loss as underlined by previous investigations (Zuckerman et al., 2003 (link)).
Apomorphine (APO, 0.125 mg/kg) (Merck Sigma-Aldrich) was dissolved in a solution containing 0.9% NaCl with 0.1 mg/ml ascorbic acid (pH 7.2) to prevent oxidation. D-Amphetamine sulfate (AMPH, 0.1 mg/kg) (Merck Sigma-Aldrich) was dissolved in a solution containing 0.9% NaCl. APO and AMPH were administered subcutaneously and intraperitoneally in an injection volume of 1 and 2 ml/kg, respectively.

Testing conditions, lighting and amphetamine dose were all as previously described^{11 (link),28 (link)}. Briefly, the animals were first acclimatized to the open field for 20 min and were then injected with sterile 0.9% saline and immediately returned to the same arenas for another 20 min. Subsequently, the animals were injected intraperitoneally (i.p.) with D-amphetamine sulfate (=AMPH; Sigma-Aldrich, Switzerland) at dose of 2.5 mg/kg (5 ml/kg) and monitored for a period of 60 min.

d-Amphetamine sulfate (AMPH; Sigma-Aldrich, Dorset, United Kingdom) was dissolved in 0.9% saline. All AMPH injections were administered i.p. at a volume of 0.1 ml/10 g. A ‘recreational-like’ dose of 4 mg/kg was used to achieve peak plasma AMPH levels of 1300 ± 79 ng/mL 5 min post-injection, consistent with plasma levels induced by recreational use of AMPH in humans. A low, ‘Adderall-like’ dose (ALD) of 0.5 mg/kg was used to achieve peak plasma levels of 97 ± 21 ng/mL, in line with those observed following therapeutic administration in humans⁶³ .